Hepatic Encephalopathy Marketembed
The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is expected to witness a CAGR of 6.3% during 2018 – 2026.
Hepatic Encephalopathy Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the liver disease: cirrhosis. The inability of the liver to metabolize ammonia results in a buildup of ammonia, which can cross the blood–brain barrier and cause significant neurocognitive impairment. A significant number of patients with cirrhosis may experience HE and may be at high risk of recurrent HE. The severity of hepatic encephalopathy can be broadly categorized into two classes: Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). OHE is associated with high rates of mortality and hospitalizations and poor quality of life. Factors such as infections, gastrointestinal bleeding, metabolic disturbance, and dietary protein overload may cause OHE. According to a study conducted by the U.S. National Library of Medicine in 2016, 30 to 50% of patients who have cirrhosis during their clinical care are likely to develop OHE. Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2596 The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is expected to witness a CAGR of 6.3% during the forecast period (2018 – 2026). Increasing number of drugs in pipeline for the treatment of HE is expected to drive the market growth during the forecast period There are different types of therapeutic drugs in pipeline for the treatment of HE. Increasing number of products in pipeline for the treatment of HE is expected to drive growth of the market over the forecast period. Umecrine Cognition, a Sweden-based pharmaceutical company, is developing a therapy that represents a new target class for several major central nervous system (CNS)-related disorders. The lead compound GR3027 is presently in clinical development for HE. The company plans to demonstrate Phase II data of GR3027 for the treatment of HE in 2020. Increasing prevalence of various types of liver diseases is expected to aid in the market growth HE is a sign of poor prognosis and correlates with mortality in both patients with acute liver failure and those with cirrhosis associated with end stage liver disease. Liver cirrhosis is a gastroenterological condition that is characterized by a slow, progressive, and irreversible replacement of liver cells by fibrous tissue (scar) that prevents normal liver functioning. According to the National Center for Biotechnology Information (NCBI): 2014, generally liver cirrhosis affects up to 1% of the U.S. and EU population. Between 180,000 and 290,000 patients with cirrhosis in the U.S. are hospitalized due to complications of HE. Once HE develops, mortality reaches 22-35% after five years. HE is also associated with increased hospitalization and treatment costs. Moreover, subtle signs of HE are observed in around 70% of patients with cirrhosis. Report includes chapters which deeply display the following deliverable about industry : • Hepatic Encephalopathy Market Research Objective and Assumption • Hepatic Encephalopathy Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Hepatic Encephalopathy Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Hepatic Encephalopathy Market, By Regions • Hepatic Encephalopathy Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Hepatic Encephalopathy Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Hepatic Encephalopathy Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Hepatic Encephalopathy Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key Players Key players operating in the global hepatic encephalopathy market include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V. Detailed Segmentation: Global Hepatic Encephalopathy Market, By Drug Class: • Antibiotic • Laxatives • Others Global Hepatic Encephalopathy Market, By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/ hepatic-encephalopathy-market-2596 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]